ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels

ADAM10 is the main α-secretase acting in the non-amyloidogenic processing of APP. We hypothesized that certain rare ADAM10 variants could increase the risk for AD by conferring the age-related downregulation of α-secretase. The ADAM10 gene was sequenced in 103 AD cases (82% familial) and 96 cognitively preserved nonagenarians. We examined rare variants (MAF < 0.01) and determined their potential association in the AD group with lower CSF protein levels, as analyzed by means of ELISA, and Western blot (species of 50 kDa, 55 kDa, and 80 kDa). Rare variants were found in 15.5% of AD cases (23% early-onset, 8% late-onset) and in 12.5% of nonagenarians, and some were group-specific. All were intronic variants except Q170H, found in three AD cases and one nonagenarian. The 3′UTR rs74016945 (MAF = 0.01) was found in 6% of the nonagenarians (OR 0.146, p = 0.057). Altogether, ADAM10 total levels or specific species were not significantly different when comparing AD with controls or carriers of rare variants versus non-carriers (except a Q170H carrier exhibiting low levels of all species), and did not differ according to the age at onset or APOE genotype. We conclude that ADAM10 exonic variants are uncommon in AD cases, and the presence of rare intronic variants (more frequent in early-onset cases) is not associated with decreased protein levels in CSF.

[1]  L. Jia,et al.  Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.

[2]  S. Aldred,et al.  The role of ADAM10 in astrocytes: Implications for Alzheimer’s disease , 2022, Frontiers in Aging Neuroscience.

[3]  Nick C Fox,et al.  Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease , 2022, Nature Genetics.

[4]  T. Lang,et al.  The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by α-secretase ADAM10 , 2022, The Journal of biological chemistry.

[5]  G. Forloni,et al.  The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  P. Manzine,et al.  ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer’s Disease , 2021, International journal of molecular sciences.

[7]  P. Manzine,et al.  ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study , 2020, Alzheimer's research & therapy.

[8]  A. Jiménez-Escrig,et al.  α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease , 2020, Alzheimer's research & therapy.

[9]  M. Tomlinson,et al.  The metalloproteinase ADAM10 requires its activity to sustain surface expression , 2020, Cellular and Molecular Life Sciences.

[10]  P. Bovolenta,et al.  Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer’s disease pathogenesis , 2019, Nature Neuroscience.

[11]  P. Manzine,et al.  ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[13]  Timothy J. Hohman,et al.  Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.

[14]  Ke Li,et al.  Influence of ADAM10 Polymorphisms on Plasma Level of Soluble Receptor for Advanced Glycation End Products and The Association With Alzheimer’s Disease Risk , 2018, Front. Genet..

[15]  K. Blennow,et al.  Levels of ADAM10 are reduced in Alzheimer’s disease CSF , 2018, Journal of Neuroinflammation.

[16]  O. Forlenza,et al.  Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[17]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[18]  P. Manzine,et al.  Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment , 2018, Pharmaceuticals.

[19]  E. Marcello,et al.  Synaptic dysfunction in Alzheimer's disease: From the role of amyloid β-peptide to the α-secretase ADAM10. , 2017, European journal of pharmacology.

[20]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[21]  A. Fellgiebel,et al.  Increase of α-Secretase ADAM10 in Platelets Along Cognitively Healthy Aging. , 2016, Journal of Alzheimer's disease : JAD.

[22]  E. Hol,et al.  ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[23]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[24]  Huadong Zhou,et al.  Genetic Association Between APP, ADAM10 Gene Polymorphism, and Sporadic Alzheimer’s Disease in the Chinese Population , 2015, Neurotoxicity Research.

[25]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[26]  R. Tanzi,et al.  ADAM10 Missense Mutations Potentiate β-Amyloid Accumulation by Impairing Prodomain Chaperone Function , 2013, Neuron.

[27]  T. Montine,et al.  ADAM10 expression and promoter haplotype in Alzheimer's disease , 2012, Neurobiology of Aging.

[28]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[29]  J. Buxbaum,et al.  Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease , 2012, Neurobiology of Aging.

[30]  L. Tan,et al.  Genetic association between ADAM10 gene polymorphism and Alzheimer's disease in a Northern Han Chinese population , 2011, Brain Research.

[31]  A. Kurz,et al.  Lack of evidence to support the association of polymorphisms within the alpha- and beta-secretase genes (ADAM10/BACE1) with Alzheimer's disease , 2011, Neurobiology of Aging.

[32]  M. Giustetto,et al.  Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. , 2010, Brain : a journal of neurology.

[33]  E. Kremmer,et al.  ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons , 2010, The EMBO journal.

[34]  K. Elliott,et al.  Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. , 2009, Human molecular genetics.

[35]  J. Neuhaus,et al.  Comparison of family histories in FTLD subtypes and related tauopathies , 2005, Neurology.

[36]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[37]  M. Luca,et al.  α-Secretase ADAM10 as Well as αAPPs Is Reduced in Platelets and CSF of Alzheimer Disease Patients , 2002, Molecular medicine.